Fig. 1.
Percentage of HIF-1α–positive cells in samples from baseline and post-treametment tumor bisopises from seven evaluable patients, reported per patient (A) and as mean ± SD (B). Immunohistochemistry staining for HIF-1α shown for patient 4 (breast cancer) at baseline and after two cycles of topotecan (C).